Scientist , Translational Genomics & Gene Therapy

If you are unable to complete this application due to a disability, contact this employer to ask for an accommodation or an alternative application process.

Salary Range: $ to $ annually.

Charlestown, MA

Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. We are advancing a diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care.

Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases.

We are seeking a highly motivated and scientifically rigorous Scientist I to join our Discovery and Translational Development team. This individual will contribute to the advancement of innovative genomic medicine programs for rare cardiomyopathies and neuromuscular diseases, spanning both preclinical and clinical-stage programs.

This is an exciting opportunity for a driven scientist who wants to work at the intersection of discovery biology, translational science, and clinical development. The successful candidate will report to a Scientific Lead and will play an important role in generating, interpreting, and communicating data that helps move programs from concept through clinical execution.

We are looking for someone who understands the promise and complexity of gene therapy and genomic medicines, can think critically in real time, and is energized by solving hard scientific problems in a fast-moving environment. This is an on-site position based out of our HQ in Charlestown, MA.

• Support the scientific execution of preclinical and clinical-stage programs in rare neuromuscular and cardiovascular diseases.
• Design, coordinate, and interpret studies that inform program strategy, candidate selection, mechanism of action, translational biomarkers, dose selection, and clinical development.
• Work closely with Scientific Leads to advance program priorities, identify key scientific questions, and develop data-driven recommendations.
• Collaborate cross-functionally with platform, research, clinical, regulatory, bioanalytical, CMC, pharmacology, toxicology, and program management teams.
• Analyze and synthesize complex datasets across in vitro, in vivo, translational, and clinical studies.
• Contribute to experimental strategy for AAV gene therapy and other genomic medicine approaches, including vector biology, tissue targeting, expression, efficacy, safety, immunology, and translational relevance.
• Help identify and resolve scientific and technical challenges that arise during program execution.
• Prepare high-quality scientific summaries, presentations, study reports, and decision-making materials for internal governance forums.
• Engage with external collaborators, CROs, academic investigators, and scientific advisors as needed.
• Stay current with advances in gene therapy, genomic medicines, rare disease biology, translational biomarkers, and competitive programs.
• Operate with scientific curiosity, urgency, accountability, and a strong commitment to developing meaningful therapies for patients.

• PhD in molecular biology, genetics, cell biology, pharmacology, neuroscience, cardiovascular biology, muscle biology, or a related discipline and 0-2+ years of relevant postdoctoral, industry, or translational research experience preferred; or equivalent experience in biotechnology, pharmaceutical, or translational research settings.
• Experience with gene therapy, AAV biology, genomic medicines, RNA-based therapeutics, genetic disease, or related therapeutic platforms strongly preferred.
• Strong understanding of preclinical study design, translational biology, and the use of disease models…